GlaxoSmithKline Pharmaceuticals (BOM:500660) EV-to-FCF: (As of Jul. 24, 2026)

GlaxoSmithKline Pharmaceuticals  (BOM:500660) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

GlaxoSmithKline Pharmaceuticals's PE Ratio (TTM) for today is calculated as:

GlaxoSmithKline Pharmaceuticals's share price for today is ₹2494.20.
GlaxoSmithKline Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹61.150.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.

GlaxoSmithKline Pharmaceuticals EV-to-FCF Related Terms

The historical data trend for GlaxoSmithKline Pharmaceuticals's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Pharmaceuticals EV-to-FCF Chart

GlaxoSmithKline Pharmaceuticals Annual Data
	Trend	Mar17	Mar18	Mar19	Mar20	Mar21	Mar22	Mar23	Mar24	Mar25	Mar26
EV-to-FCF		Get a 7-Day Free Trial					32.58	47.24	56.43	36.56	42.40

GlaxoSmithKline Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EV-to-FCF	Get a 7-Day Free Trial															36.56	0.00	0.00	0.00	42.40

BOM:500660 vs LLY, JNJ, ABBV: EV-to-FCF Comparison

For the Drug Manufacturers - General subindustry, GlaxoSmithKline Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GlaxoSmithKline Pharmaceuticals EV-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where GlaxoSmithKline Pharmaceuticals's EV-to-FCF falls into.

GlaxoSmithKline Pharmaceuticals EV-to-FCF Calculation

GlaxoSmithKline Pharmaceuticals's EV-to-FCF for today is calculated as:

GlaxoSmithKline Pharmaceuticals's current Enterprise Value is ₹395,302 Mil.
GlaxoSmithKline Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Pharmaceuticals Business Description